Neurology/case reportA Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration
Introduction
Orolingual angioedema can be a life-threatening crisis initiated by genetic factors or by certain foods, medications, infections, or stress. Hereditary angioedema has edematous and inflammatory consequences similar to those of other causes, but it is due to qualitative or quantitative dysfunction of C1 esterase inhibitor.1, 2 This can result in excessive release of bradykinin and histamine, leading to increased vascular permeability and edema. Icatibant, ecallantide, and plasma-derived C1 esterase inhibitor are approved hereditary angioedema treatments that target areas to prevent and reverse orolingual angioedema.
Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA) treatment of acute ischemic stroke, with a reported incidence of between 1% and 5%.3, 4, 5, 6, 7, 8, 9, 10 The frontal, insular, and peri-insular regions are often involved and are believed to play a role in the pathophysiology of stroke-associated angioedema. This association is thought to be due to proximity to the facial cortex, in conjunction with increased sympathetic tone and peripheral vasoconstriction, leading to cerebral dysregulation.10, 11 Orolingual angioedema developing after tPA administration for acute ischemic stroke may manifest as unilateral swelling of the lips, tongue, and face. The resultant edema is commonly contralateral to the ischemic lesion, which is believed to be due to the infarction’s triggering autonomic dysfunction and vasomotor changes in the hemiparetic side.10 Despite this distinct presentation, available literature has demonstrated equal representation of bilateral, contralateral, and ipsilateral edema.5, 7, 11
The proposed mechanism of tPA-induced orolingual angioedema is shown in Figure 1.1, 6, 7, 9, 11 Plasminogen is activated to plasmin by tPA, which leads to fibrinolysis and activation of the complement cascade and kinin pathway. Complement cascade activation causes anaphylotoxin release, which results in bradykinin production and vasodilatation. Patients receiving angiotensin-converting enzyme inhibitors who also receive tPA may be at higher risk for angioedema.3, 4, 7, 10 Angiotensin-converting enzyme inhibitors block plasma kinases responsible for bradykinin inactivation, resulting in elevated baseline bradykinin concentrations. Complement activation, histamine release, and bradykinin release are believed to be the primary mediators of tPA-associated angioedema.1, 2, 5, 6, 7, 9, 10, 11, 12, 13 Given a lack of direct treatment for tPA-induced orolingual angioedema, the current treatment recommendations suggest supportive care, corticosteroids, epinephrine, and histamine antagonists.3, 4, 5, 7, 9 There is potential to use hereditary angioedema therapies in patients presenting with tPA-induced orolingual angioedema refractory to the first-line therapies.
Section snippets
Case Report
A 72-year-old white man with a history of coronary artery disease, myocardial infarction requiring 2 drug-eluting stents, hypertension, and hyperlipidemia presented with sudden-onset right-sided weakness, dysarthria, and a National Institutes of Health Stroke Scale score of 10. Formal medication reconciliation was performed and included atenolol 25 mg, lisinopril 20 mg, hydrochlorothiazide 12.5 mg, atorvastatin 80 mg, aspirin 81 mg, and vitamin supplements. The patient received a diagnosis of
Discussion
Because of tPA-associated orolingual angioedema’s rarity, no targeted treatment exists for it. Symptomatic management with supportive care, corticosteroids, epinephrine, and histamine antagonists is considered first-line therapy.3, 4, 5, 7, 9 Rapid progression with airway compromise and pending asphyxia may occur despite these treatments.5, 7 Food and Drug Administration–approved therapies for hereditary angioedema that antagonize bradykinin or target the kallikrein-kinin system are believed to
References (22)
- et al.
Pathways for bradykinin formation and inflammatory disease
J Allergy Clin Immunol
(2002) - et al.
Current update on cellular and molecular mechanisms of hereditary angioedema
Ann Allergy Asthma Immunol
(2014) - et al.
Anaphylactic shock associated with intravenous thrombolytics
Am J Emerg Med
(2014) - et al.
Asymmetric angioneurotic edema associated with thrombolysis for acute stroke
Ann Emerg Med
(1997) - et al.
Angioedema after administration of rtPA for ischemic stroke: a case report
Air Med J
(2011) - et al.
Simultaneous bilateral thalamic hemorrhages following the administration of intravenous tissue plasminogen activator
Arch Phys Med Rehabil
(1997) - et al.
Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series
Ann Emerg Med
(2010) - et al.
Orolingual angioedema with alteplase administration for treatment of acute ischemic stroke
J Emerg Med
(2013) - et al.
Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies
Neurohospitalist
(2011) - et al.
Raising awareness of orolingual angioedema as a complication of thrombolysis in acute stroke patients
Cerebrovasc Dis
(2009)
Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke
J Neurol
Cited by (28)
Tissue plasminogen activator (alteplase)-induced angioedema after intravenous thrombolysis
2022, Revue Francaise d'AllergologieAlteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
2022, Research and Practice in Thrombosis and HaemostasisIcatibant for the treatment of orolingual angioedema following the administration of tissue plasminogen activator
2018, American Journal of Emergency MedicineCitation Excerpt :Limitations of this case are the lack of research and case studies regarding itcatibant's use for rt-PA-induced angioedema. One case report of the successful use of plasma-derived C-1 esterase inhibitor for the management of rt-PA-induced angioedema exists, and there has only been one other case report of the use of icatibant [9,10]. In patients who develop rt-PA-induced angioedema that are unresponsive to traditional therapy, icatibant may be an adjunct treatment option to improve outcomes and avoid emergent and/or invasive airway management, and warrants further investigation.
Icatibant as a Potential Treatment of Life-Threatening Alteplase-Induced Angioedema
2018, Journal of Stroke and Cerebrovascular DiseasesIcatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema
2024, European Journal of Neurology
Supervising editors: William J. Meurer, MD, MS; Donald M. Yealy, MD
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist.